CV hospitalizations and urgent HF hospitalization in adult patients with wild-type or hereditary transthyretin-mediated amyloidosis with cardiomyopathy (ATTR-CM), according to a company press release.

People with transthyretin cardiac amyloidosis (ATTR-CA ... (Attruby), another TTR stabilizer for treating wild-type or variant ATTR-CM. During the study period covered by Masri and colleagues ...

The costs of Part D drug plans can vary by location, plan provider, and plan type. Transthyretin is a specific amyloid protein that your body deposits into your heart if you have ATTR-CM.

Transthyretin Amyloidosis Treatment Market explores key drug advances, regulatory developments, and growth trends through 2035 ...

The cost of Part D drug plans can vary by location, plan provider, and plan type. Transthyretin is a specific amyloid protein deposited in a person’s heart if they have ATTR-CM. The protein ...

The European Commission has approved BridgeBio's acoramidis for life-threatening heart disorder transthyretin amyloidosis ... cardiomyopathy in wild-type or variant ATTR patients and will be ...

Vutrisiran improved mortality and recurrent CV risks independent of disease severity and improved several other endpoints for ...

has approved a supplemental new drug application for vutrisiran for the treatment of wild-type or hereditary transthyretin-mediated amyloid cardiomyopathy (ATTR-CM) to reduce cardiovascular death ...

Vutrisiran, a transthyretin-directed small interfering RNA, had its approval expanded to treat cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) in adults to ...

Acoramidis’s hazard ratio of .41 for time to ACM or first CVH versus placebo in the ATTRibute-CM study subgroup of ATTRv-CM patients achieved ...

OXLUMO for primary hyperoxaluria type 1; and Leqvio for hypercholesterolemia. It also develops vutrisiran, which is in phase III clinical trial for transthyretin amyloidosis (ATTR) with ...